NASDAQ:MNOV
MediciNova Stock News
$1.42
-0.0100 (-0.699%)
At Close: May 17, 2024
MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
10:30am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
FDA Completes Protocol Review and Study May Proceed FDA Completes Protocol Review and Study May Proceed
MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking
09:47am, Friday, 08'th Apr 2022
MediciNova Inc (NASDAQ: MNOV) announced that secondary analysis of the Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) was published in the journal Alcoholism: Clinical and Experi
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
11:00pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
LA JOLLA, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
10:30am, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
LA JOLLA, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest
10:30am, Tuesday, 15'th Mar 2022 GlobeNewswire Inc.
LA JOLLA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
11:30am, Monday, 28'th Feb 2022 GlobeNewswire Inc.
LA JOLLA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs
11:30am, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
LA JOLLA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (
MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterol
11:40am, Tuesday, 01'st Feb 2022 Seeking Alpha
MediciNova (MNOV) received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia,
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
11:30am, Tuesday, 01'st Feb 2022 GlobeNewswire Inc.
LA JOLLA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (
MediciNova stock jumps after securing Canada patent for MN-001/002 for hepatic ballooning
11:54am, Monday, 31'st Jan 2022 Seeking Alpha
MediciNova (MNOV) gains 9.7% premarket after receiving a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
11:30am, Monday, 31'st Jan 2022 GlobeNewswire Inc.
LA JOLLA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (
MediciNova receives new European patent for ibudilast for alcohol use disorder
11:43am, Thursday, 27'th Jan 2022 Seeking Alpha
MediciNova (MNOV) has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
11:30am, Thursday, 27'th Jan 2022 GlobeNewswire Inc.
LA JOLLA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
01:29pm, Wednesday, 26'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaz
MediciNova secures new European patent for MN-001 and MN-002 for hepatic ballooning
11:47am, Wednesday, 26'th Jan 2022 Seeking Alpha
MediciNova (MNOV) that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a
